Fluorapacin Drug Asset Due Diligence Report 2026

This Fluorapacin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

209

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Fluorapacin can convert its Small molecule drug profile and Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fluorapacin (query alias: Fluorapacin)
Modality / target	Small molecule drug; Tubulin; Tubulin inhibitors
Highest global status	Phase 2
Originator	Acea Bio (Hangzhou) Co., Ltd.
Active developers	ACEA Therapeutics, Inc.

The MCP disease footprint includes Lung Cancer, Non-Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20130893	Phase 1	Completed	Not disclosed	Primary endpoint not disclosed in English source
CTR20130888	Phase 1	Recruiting	Not disclosed	Primary endpoint not disclosed in English source
NCT01361529	Phase 1	Unknown status	30	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)

Phase 3; n=220; evaluation: Positive. Reported fields: Median TTP(time to progression) = 5.7 Month ; Median TTP(time to progression) = 3.8 Month

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fluorapacin addresses Lung Cancer, Non-Small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 209 matched transaction record(s) under the scope “target-level comparable: Tubulin.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Tubulin records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-09-03	Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal	Discontinued	US$12.0M upfront; US$1,015.0M milestones
2026-08-12	ArriVent BioPharma, Inc. Enters Into Exclusive Licensing Agreement With Shanghai Allist Pharmaceuticals Co., Ltd. For ARR-002 In Greater China	Phase 1	US$80.6M stated total
2026-06-03	Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Remotely triggered therapy”. The milestone feed surfaced a patent-application signal described as “Synthetic process for anticancer drug fluorapacin and trisulfide derivatives”. The milestone feed surfaced a patent-application signal described as “Synthesis and production process of anti-cancer medicament bis(4-fluorobenzyl) trithioether and organic trithioether derivative”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO